Late relapse of primary central nervous system lymphoma. 2017

Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
a Department of Neurosurgery , Brain Research Institute, Niigata University , Niigata , Japan.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses

Related Publications

Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
May 2011, Neuro-oncology,
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
May 2007, Leukemia & lymphoma,
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
January 2016, SpringerPlus,
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
September 2017, Clinical case reports,
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
May 2004, Clinical oncology (Royal College of Radiologists (Great Britain)),
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
December 2018, Cureus,
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
February 2014, Clinical lymphoma, myeloma & leukemia,
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
January 2015, International ophthalmology clinics,
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
January 2018, Therapeutic advances in neurological disorders,
Ryuya Yamanaka, and Ken Morii, and Yoshikatsu Shinbo, and Masakazu Sano, and Jumpei Homma, and Naoto Tsuchiya, and Naoki Yajima, and Yoshihiro Tsukamoto, and Ryouske Ogura, and Manabu Natsumeda, and Hiroshi Aoki, and Katsuhiko Akiyama, and Takafumi Saitoh, and Tetsuro Tamura, and Hiroaki Hondoh, and Atsushi Kawaguchi, and Hitoshi Takahashi, and Yukihiko Fujii
April 1985, Journal of neurosurgery,
Copied contents to your clipboard!